Expert Perspectives on Best Practices for Diagnosis and Management of Spinal Muscular Atrophy.

Slides:



Advertisements
Similar presentations
Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer
Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
State of the Art in BRCA-Mutated Ovarian Cancer
Optimal Management of Spinal Muscular Atrophy
New Horizons for SMA.
Evolving Paradigms in the Management of HR-Positive Breast Cancer
Systemic Lupus Erythematosus
New Psoriasis Treatments
Improving Survival in Glioblastoma Multiforme
Advances in Managing Inhibitors in Patients With Hemophilia A
Progression After Cancer Immunotherapy in Advanced NSCLC
Clues to a Diagnosis: A Focus on Light-Chain Amyloidosis
Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update
New Standards of Care in ALK-Translocated Advanced NSCLC
Mid-Year Hemophilia Update
Induction Chemotherapy for Patients With High-Risk or Secondary AML
Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.
PARP Inhibitors and Cancer: What Do You Need to Know?
Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.
BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma
The Resurgence of Topical Treatments Across a Spectrum of Psoriasis
Navigating the Data and Evolving Our Approach
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
Addressing Disease Burden in Asthma
Optimizing Management of Advanced Bladder Cancer
Individualizing Care in Ovarian Cancer
Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.
Postpartum Depression
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Evaluating Next-Generation BTK Inhibitors
Case Studies in Unresectable Hepatocellular Carcinoma
Hyperhidrosis Is Burdensome!
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Ask the Experts.
Immunotherapy for cSCC
The Science of Gene Therapy for Hemophilia
Optimizing Frontline Care for Older Patients With Multiple Myeloma
New Data on Emerging Treatments for Psoriasis
How to Select Therapy In Newly Diagnosed CLL
Advancing Care Across the Spectrum of Pancreatic Cancer
Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.
Personalizing Management in the Care of Patients With Advanced Sarcoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.
Advances in Peanut Allergy
Updates in the Management of Acute Promyelocytic Leukemia
Getting to Grips With the Science of CGRP and Migraine
Advances in Immunotherapy for Peanut Allergy
Guide to Atopic Dermatitis
Chronic Myeloid Leukemia Challenge
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Best Practices in SMA.
Patient Questions and Expert Answers in Psoriasis:
The Psychiatrist's Role in Tardive Dyskinesia
Patient and Clinician Perspectives on Preventive Therapy for Migraine
Novel Concepts in the Management of RCC
From Adjuvant to Metastatic in Melanoma
Prioritizing Prevention of HPV-Related Disease
The Psychiatrist's Role in Tardive Dyskinesia
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Checkpoint Inhibitors in First-Line Advanced NSCLC
VKA Reversal and LVADs.
CDK4/6 Inhibitors.
Updates in SMA From an International Muscle Meeting
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
SMN1 and SMN2 contribute to spinal muscular atrophy (SMA).
Importance of Early Diagnosis and Management in SMA
Immune Checkpoint Inhibitors in Lung Cancer
Exploring the Use of Adeno-Associated Virus for Gene Therapy
Presentation transcript:

Expert Perspectives on Best Practices for Diagnosis and Management of Spinal Muscular Atrophy

This program will include a discussion of investigational agents not approved by the FDA for use in the US and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction to SMA

Spectrum of SMA Severity

Videos of Children With SMA

Suspect SMA? Order Genetic Testing

Genetics of SMA: Chromosome 5q13

SMN2 Gene Makes Small Amount of Protein

Number of SMN2 Copies Affects SMA Severity

Genetic Testing for SMA

Pathophysiology of SMA

Multidisciplinary Care of Patients With SMA

Mechanisms of Action of SMA Therapies

Phase 1 Trial of AVXS-101

Motor Response in High-Dose Group

Further Trials of AVXS-101

Other Investigational Agents for SMA

Principal Clinical Trials of Nusinersen

Nusinersen: ENDEAR Design

Nusinersen: ENDEAR Results

Nusinersen: NURTURE Interim Results

Newborn Screening for SMA

Other Changes Ahead in SMA Management

Summary

Abbreviations